Sevoflurane promotes the apoptosis of laryngeal squamous cell carcinoma in-vitro and inhibits its malignant progression via miR-26a/FOXO1 axis

References

• Nocini R, Molteni G, Mattiuzzi C, Lippi G. Updates on larynx cancer epidemiology. Chin J Cancer Res. Feb 2020;32(1):18-25.
   Google Scholar
• El-Serag HB, Hepworth EJ, Lee P, Sonnenberg A. Gastroesophageal reflux disease is a risk factor for laryngeal and pharyngeal cancer. Am J Gastroenterol. Jul 2001;96:2013–2018.
   Google Scholar
• Ludwig ML, Birkeland AC, Hoesli R, et al. medicine. Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. 2016;13:87.
   Google Scholar
• Zhang S-Y, Lu Z-M, Luo X-N, et al. Retrospective analysis of prognostic factors in 205 patients with laryngeal squamous cell carcinoma who underwent surgical treatment. 2013;8:e60157.
   Google Scholar
• Birkeland AC, Beesley L, Bellile E, et al. neck. Predictors of survival after total laryngectomy for recurrent/persistent laryngeal squamous cell carcinoma. 2017;39:2512–2518.
   Google Scholar
• Longhini F, Bruni A, Garofalo E, et al. Ammendola MJCm, research. Anesthetic strategies in oncological surgery: not only a simple sleep, but also impact on immunosuppression and cancer recurrence. 2020;12:931.
   Google Scholar
• Jun I-J, Jo J-Y, Kim J-I, et al. Choi I-CJSr. Impact of anesthetic agents on overall and recurrence-free survival in patients undergoing esophageal cancer surgery: a retrospective observational study. 2017;7:1–9.
   Google Scholar
• Liang H, Gu M, Yang C, et al. Sevoflurane inhibits invasion and migration of lung cancer cells by inactivating the p38 MAPK signaling pathway. 2012;26:381–392.
   Google Scholar
• Wu T, Sun L, Wang C, et al. Sevoflurane Suppresses the Migration, Invasion, and Epithelial-Mesenchymal Transition of Breast Cancer Cells Through the miR-139-5p/ARF6 Axis. 2021;258:314–323.
   Google Scholar
• Pang H, Xu X, Dai L, et al. MicroRNA‑195 is associated with regulating the pathophysiologic process of human laryngeal squamous cell carcinoma. Mol Med Rep. 2018;17:5283–5291.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhu Q, Lu L, et al. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1. 11(91–102):2020.
   Google Scholar
• Baltimore D, Boldin MP, O’connell RM, et al. MicroRNAs: new regulators of immune cell development and function. Nat Immunol. 2008;9(8):839.
   PubMed Web of Science ®Google Scholar
• Si W, Shen J, Zheng H, et al. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics. 2019;11:25.
   PubMed Web of Science ®Google Scholar
• LA Y, Norbury CJ, Gilbert RJ. The long and short of microRNA. Cell. 2013;153(3):516–519.
   PubMed Web of Science ®Google Scholar
• Wang F, Song G, Liu M, et al. miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line. FEBS Lett. 2011;585(20):3263–3269.
   PubMed Web of Science ®Google Scholar
• Li M, Tian L, Wang L, et al. Down-regulation of miR-129-5p inhibits growth and induces apoptosis in laryngeal squamous cell carcinoma by targeting APC. PLoS One. 2013;8(10):e77829.
   PubMed Web of Science ®Google Scholar
• Zhang T, Liu M, Wang C, et al. Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res. 2011;31:3859–3863.
   PubMed Web of Science ®Google Scholar
• Wei Z, Chang K, Fan C, et al. MiR-26a/miR-26b represses tongue squamous cell carcinoma progression by targeting PAK1. Cancer Cell Int. 2020;20(1):82.
   PubMed Web of Science ®Google Scholar
• Lian R, Lu B, Jiao L, et al. MiR-132 plays an oncogenic role in laryngeal squamous cell carcinoma by targeting FOXO1 and activating the PI3K/AKT pathway. Eur J Pharmacol. 2016;792:1–6.
   PubMed Web of Science ®Google Scholar
• Zhao X, Gan L, Pan H, et al. Multiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of phosphorylation- and 14-3-3-dependent and -independent mechanisms. Biochem J. 2004;378(3):839–849.
   PubMedGoogle Scholar
• YY K, Lin HP, Huo C, et al. Caffeic acid phenethyl ester suppresses proliferation and survival of TW2.6 human oral cancer cells via inhibition of Akt signaling. Int J Mol Sci. 2013;14(5):8801–8817.
   PubMed Web of Science ®Google Scholar
• Khandelwal A, Sharma U, Barwal TS, et al. Circulating miR-320a Acts as a Tumor Suppressor and Prognostic Factor in Non-small Cell Lung Cancer. Mol Med Rep. Jan 11 (2021).
   Google Scholar
• Wei J, Ma Z, Li Y, et al. miR‑143 inhibits cell proliferation by targeting autophagy‑related 2B in non‑small cell lung cancer H1299 cells. 11(571–6):2015.
   Google Scholar
• Liang H, Yang CX, Zhang B, et al. Sevoflurane suppresses hypoxia-induced growth and metastasis of lung cancer cells via inhibiting hypoxia-inducible factor-1α.  J Anesth. Dec 2015;29:821–830.
   Google Scholar
• P-P W, S-Y D, Y-Y S, et al. MYCT1 Inhibits the Adhesion and Migration of Laryngeal Cancer Cells Potentially Through Repressing Collagen VI. Front Oncol. 10 (2021).
   Google Scholar
• Wu Z, Lu B, Li X, et al. Physiology. Micro RNA‐26a inhibits proliferation and tumorigenesis via targeting CKS 2 in laryngeal squamous cell carcinoma. Clin Exp Pharmacol Physiol. May 2018;45:444–451.
   Google Scholar
• Fukumoto I, Hanazawa T, Kinoshita T, et al. MicroRNA expression signature of oral squamous cell carcinoma: functional role of microRNA-26a/b in the modulation of novel cancer pathways. Br J Cancer. 2015;112(5):891–900.
   PubMed Web of Science ®Google Scholar
• Jin Z, Li R, Liu J, et al. pathophysiology, pharmacology. Long-term prognosis after cancer surgery with inhalational anesthesia and total intravenous anesthesia: a systematic review and meta-analysis.  Int J Physiol Pathophysiol Pharmacol. 2019;11:83.
   Google Scholar
• RSJ W, Jo E, CC R. Apoptosis in cancer: from pathogenesis to treatment. Biotechnol Annu Rev. 2011;30:1–14.
   Google Scholar
• SA E, Box C, Court W. Cell migration/invasion assays and their application in cancer drug discovery. J Exp Clin Cancer Res. Sep 11(391–421):2005.
   Google Scholar
• Thomas B, Raghu K, Angela NMJNRC, Weinberg RA. EMT in cancer. Nat Rev Cancer. Feb 2018;18:128–134.
   Google Scholar
• Singh A, Settleman JJO. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. Aug  2010; 29(4741–51).
   Google Scholar
• Tanaka S, Ishikawa M, Arai M, et al. Changes in microRNA expression in rat lungs caused by sevoflurane anesthesia: a TaqMan® low-density array study. Biomed Res. 2012;33:255–263.
   Google Scholar
• Deng M, H-l T, X-h L, et al. miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer. PLoS One. 2013;8:e72662.
   Google Scholar
• Ma W, Gilligan BM, Yuan J, et al. oncology. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. May 2016;9:1–21.
   Google Scholar
• Goto T, Takano M, Albergaria A, et al. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene. Jan 2008;27:9–19.
   Google Scholar
• Zhang H, Pan Y, Zheng L, et al. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res. May 1,2011;71:3257–3267.
   Google Scholar
• Huang H, Regan KM, Lou Z, et al. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science. Oct 13, 2006;314(294–7).
   Google Scholar
• Dong T, Zhang Y, Chen Y, et al. FOXO1 inhibits the invasion and metastasis of hepatocellular carcinoma by reversing ZEB2-induced epithelial-mesenchymal transition. Oncotarget. Jan 3, 1703;2017:8.
   Google Scholar